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PCLINICAL RESEARCH Coronary Artery Disease
Cardiac Rehabilitation and
Survival in Older Coronary Patients
Jose A. Suaya, MD, PHD,* William B. Stason, MD, MSCI,* Philip A. Ades, MD,†
Sharon-Lise T. Normand, PHD,‡ Donald S. Shepard, PHD*
Waltham and Boston, Massachusetts; and Burlington, Vermont
Objectives This study assessed the effects of cardiac rehabilitation (CR) on survival in a large cohort of older coronary
patients.
Background Randomized controlled trials and meta-analyses have shown that CR improves survival. However, trial partici-
pants have been predominantly middle-aged, low- or moderate-risk, white men.
Methods The population consisted of 601,099 U.S. Medicare beneficiaries who were hospitalized for coronary conditions
or cardiac revascularization procedures. One- to 5-year mortality rates were examined in CR users and nonusers
using Medicare claims and 3 analytic techniques: propensity-based matching, regression modeling, and instru-
mental variables. The first method used 70,040 matched pairs, and the other 2 techniques used the entire cohort.
Results Only 12.2% of the cohort used CR, and those users averaged 24 sessions. Each technique showed significantly
lower (p  0.001) 1- to 5-year mortality rates in CR users than nonusers. Five-year mortality relative reductions
were 34% in propensity-based matching, 26% from regression modeling, and 21% with instrumental variables.
Mortality reductions extended to all demographic and clinical subgroups including patients with acute myocar-
dial infarctions, those receiving revascularization procedures, and those with congestive heart failure. The CR
users with 25 or more sessions were 19% relatively less likely to die over 5 years than matched CR users with
24 or fewer sessions (p  0.001).
Conclusions Mortality rates were 21% to 34% lower in CR users than nonusers in this socioeconomically and clinically di-
verse, older population after extensive analyses to control for potential confounding. These results are of similar
magnitude to those observed in published randomized controlled trials and meta-analyses in younger, more se-
lected populations. (J Am Coll Cardiol 2009;54:25–33) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.078m
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coronary heart disease (CHD) is the leading cause of death
orldwide. It is also a major driver of medical care costs and
conomic costs of death and disability, especially in older
eople. Worldwide in 2002, more than 7.2 million deaths were
ttributed to CHD (1). In the U.S. alone, more than 13
illion people had CHD, more than 860,000 people had acute
yocardial infarctions (AMIs), and 480,000 people died of
HD in 2003 (2). Older Americans (age 65 years or older)
ccount for more than 55% of AMIs and 86% of CHD deaths
3). Cardiac rehabilitation (CR), which uniformly includes
rom the *Schneider Institutes for Health Policy, Heller School, Brandeis University,
altham, Massachusetts; †College of Medicine, University of Vermont, Burlington,
ermont; and the ‡Department of Health Care Policy, Harvard Medical School
nd Department of Biostatistics, Harvard School of Public Health, Boston,
assachusetts. Drs. Suaya, Stason, and Shepard were supported in part by Centers for
edicare & Medicaid Services (CMS) contracts 500-95-0060 (Task Order 02)
nd/or 500-02-0012-MDBU (Maryland and Brandeis University).f
Manuscript received October 28, 2008; revised manuscript received January 20,
009, accepted January 25, 2009.onitored aerobic exercise and varying protocols for lipid
ontrol, weight loss, or stress modification, is recommended for
atients after MIs, with stable angina, or after revascularization
ith coronary artery bypass graft (CABG) surgery or coronary
ngioplasty (4–9). Meta-analyses of randomized controlled
rials of CR have demonstrated 15% to 28% reductions in
ll-cause mortality (10–14). However, these trials included
See page 34
ery few older persons, women, members of racial/ethnic
inorities, or high-risk patients (e.g., patients with congestive
eart failure [CHF]). Hence, their results may not accurately
eflect effects in older or more sociodemographically diverse
opulations.
This study examined 1- to 5-year mortality in 601,099
edicare beneficiaries who were hospitalized in 1997 for
oronary disease or revascularization procedures with
ollow-up extended through 2002. We compared mortal-
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using 3 statistical techniques:
propensity-based matching, re-
gression modeling, and instru-
mental variables (IVs).
Methods
Study cohort. We included all
Medicare beneficiaries age 65
years and older who were hospi-
talized in 1997 in nonfederal,
acute care hospitals in the 50
U.S. states or District of Colum-
bia for coronary diagnoses or
procedures paid by Medicare, the
lmost-universal health insurance for older and disabled
mericans. The principal diagnosis codes used to identify
eneficiaries were 410.xx for AMI, 411.xx for other acute
oronary syndromes, 413.xx for stable coronary syndrome,
nd 414.xx for other chronic ischemic heart disease condi-
ions. Procedure codes included 36.1 for CABG surgery and
6.01, 36.02, 36.05, or 36.06 for percutaneous coronary
ntervention (PCI)—angioplasty or stent. Other inclusion
riteria were a hospital stay of 30 days or less (to identify
robable candidates for CR), being alive for at least 30 days
fter hospital discharge, and uninterrupted enrollment in
ee-for-service Medicare Part A and Part B during the index
ospitalization and for at least 12 months after discharge (to
btain complete billing information). The study cohort
onsisted of the 601,099 Medicare beneficiaries who met
he inclusion criteria.
ata sources and definition of CR use. Medicare’s Na-
ional Claims History File was the primary data source.
edicare’s master enrollment database included informa-
ion on date of birth, sex, race, date of death (when
pplicable), residence zip code, enrollment status over time,
edicare entitlements (Part A and Part B), and group
ealth plan membership. Census 2000 data were linked to
esidence zip code statistics as proxies for the patient’s
ocioeconomic, educational, and disability statuses. Ameri-
an Hospital Association and Medicare data were used to
etermine hospital characteristics for index admissions. Use
f CR services was defined by Medicare reimbursement for
t least 1 CR session (denoted by Current Procedure
erminology codes 93797 and 93798) within 1 year follow-
ng discharge.
rimary outcome. The primary outcome was all-cause
ortality within 5 years of discharge from the index
ospitalization. Because these survival data formed the basis
f eligibility for government benefits, there was virtually no
oss to follow-up for mortality; therefore, patients were
ensored only at the end of the follow-up period if they were
till alive.
tatistical analysis. The patient was the unit of analysis.
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass graft
CHD  coronary heart
disease
CHF  congestive heart
failure
CR  cardiac rehabilitation
IV  instrumental variable
PCI  percutaneous
coronary interventionxplanatory variables included patient sociodemographic aharacteristics (age, sex, race/ethnicity, Medicare/Medicaid
ual eligibility), distance from the center of the patient’s
esidence zip code to the nearest available CR facility within
he state of residence, health-related characteristics (type of
oronary event, type of coronary intervention, duration of
he index hospitalization, and comorbid conditions), char-
cteristics of the index hospital (state, size, teaching status,
nd availability of angiography, angioplasty, and cardiac
urgery), and the socioeconomic characteristics of the pa-
ient’s zip code (median household income, proportion
elow poverty line, average education, and prevalence of
isability) and geography (census division).
elationship between CR and mortality using propensity-
ased matching. Propensity-based matching paired CR
sers with nonusers using all observable risk factors (15–17).
sing the entire study cohort, we fit a multiple logistic
egression model of CR use as a function of the explanatory
ariables. We adjusted for clustering within index admission
ospitals and used generalized estimating equations via the
ENMOD procedure in SAS software (version 9.1, SAS
nstitute Inc., Cary, North Carolina). This model provided
he adjusted predicted probabilities (propensity scores) of
R use from 0 to 1 for each patient. Then we matched each
R user with a nonuser who had the closest propensity
core for CR use and matched exactly on sex, race, type of
ardiac event (AMI, CABG, or PCI), age category (65 to
4 years, 75 to 84 years, or 85 years and older), presence of
diagnosis of CHF, Medicare/Medicaid dual eligibility,
nd census division.
Nonusers were accepted as matches only if they were alive
or at least as many days after their hospital discharge as the
nterval between the matched CR user’s hospital discharge
nd the CR user’s first CR session. Using the GREEDY
lgorithm and a macro developed by Kosanke and Bergs-
ralh (18), all possible matches were identified (using a
ropensity caliper of 60% of the pooled SD of the logit
ropensity score). These procedures yielded 70,040 matched
airs of CR users and nonusers, the subset of the entire
ohort used in our propensity-based matching analyses. The
arge size of this cohort did not require trying to match more
han 1 nonuser to each user. Standardized differences,
efined as the difference between means divided by the
ooled SD of the 2 groups (19), were used to describe the
agnitudes of differences between groups (CR users and
onusers). Standardized differences 10% were considered
eaningful (19).
Mortality differences between matched pairs of CR users
nd nonusers overall and for demographically- and
linically-defined subgroups were estimated using Kaplan-
eier survival curves. They were tested for their homoge-
eity with the Wilcoxon signed rank test for matched pairs.
ifferences in mortality rates were assessed for 5 years after
ischarge from index hospitalizations, and their statistical
ignificances were evaluated using the McNemar test.
To evaluate these differential effects of CR by sex, race,
nd age groups, we ran a multiple logistic regression model
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June 30, 2009:25–33 Cardiac Rehabilitation and Survivaln the paired matches using 5-year mortality as the depen-
ent variable. The dichotomous predictors were CR use,
emale, white, age 75 to 84 years, age 85 years and older,
MI, CABG, percutaneous transluminal coronary angio-
lasty, CHF, and all first-order interaction terms between
R use, sex, race, and age categories. The model also
ccounted for matched pairs.
ose-response relationships between CR and mortality
sing propensity-based matching. The CR users were
ivided into low- and high-user groups based on the median
umber of CR sessions received (1 to 24 sessions and 25 or
ore sessions, respectively). The propensity-based matched
air analysis required that that the dose be treated as a
ichotomous variable. Each high-CR user was matched
ith a low-CR user on the closest logit of propensity scores
nd exact matches for sex, race, type of cardiac event (AMI,
ABG, or PCI), age category (65 to 74 years, 75 to 84
ears, or 85 years and older), and Medicare/Medicaid dual
ligibility. Low-CR users were accepted as matches only if
hey were alive the same number of days after discharge
rom their index hospitalizations as their high-user coun-
erparts when they received their 25th CR session.
elationships between CR use and mortality using re-
ression modeling. Regression modeling fit estimated the
mpact of CR on mortality with the same risk factors as
atching but applied to the entire cohort of 601,099
edicare beneficiaries. We regressed 1- to 5-year mortality
y fitting a single-equation probit model with CR use and
ll available patient and hospital characteristics as indepen-
ent variables. After calculating each patient’s probability of
eath with and without CR use at each time point, we then
stimated changes in mortality associated with CR as the
ifference between these 2 mortality rates and averaged over
he entire cohort.
elationships between CR and mortality using IVs. We
nhanced regression modeling by using IVs to protect against
esidual confounding by unobserved variables (15–17). The IV
ethod consists of selecting 1 or more variables (instru-
ents) that are correlated with the use of CR but without
ny direct effect on survival (except through the use of CR).
sing the entire cohort, we examined 2 IVs that would
ffect CR participation rates but should not otherwise affect
ortality outcomes: 1) distance to the CR facility from the
enter of the patient’s residence zip code within his/her state
f residence; and 2) density of CR facilities per 10,000
opulation age 65 years or older by state. To establish the
alidity of these 2 variables, we stratified the cohort into 2
qual-sized groups: 1) patients living closer versus more
istant from the CR facility; and 2) patients living in low-
ersus high-density CR facility areas. Although the use of
R was higher in patients living closer to CR facilities or in
igh-density CR areas, there were no significant differences
n sociodemographic, number of coronary illness episodes,
nd comorbidities between these 2 equal-sized groups.
hese very similar characteristics between these groups, andhe steps below, supported our assumption that classifying (atients on the basis of distance to CR or density of CR
acilities were not independently associated with mortality.
ecause further analysis found the effects were not linear,
ach IV was entered as a set of dummy variables based on
uintiles of distributions among CR users. We confirmed
hat each set of dummy variables was a strong predictor of
R use by fitting a multivariable single-equation probit
odel of CR use with and without the IVs but with all
easured patient and hospital characteristics. Use of CR
eclined significantly with increasing distance from the
losest CR facility and increased significantly with a higher
ensity of CR facilities.
The 2 instruments combined increased the pseudo R2 of
he model from 0.156 to 0.199 (p  0.001). Finally, to
etermine that the instruments were not directly related to
urvival, we fit a multivariable single-equation probit model
f mortality including the IVs, CR use, and measured
atient and hospital characteristics. The results indicated a
mall, but not clinically meaningful, change in the pseudo
2 associated with the IVs (for 5-year survival from 0.2188
o 0.2190, representing a relative improvement of only
.09%). We concluded that the instruments were valid and
sed them to estimate CR benefits.
The first stage of the IV model determined how much
ariance in CR use was explained by the IVs after adjusting
or measured patient and hospital characteristics (15). The
econd stage predicted survival based on the predicted
robability of CR use from the first-stage model coupled
ith all the explanatory factors except for IVs in the
rst-stage model. The resulting coefficient was considered
o be the unbiased estimate of CR effect on survival. We
sed the biprobit procedure in STATA (version 10, StataCorp.,
ollege Station, Texas) with adjustment for hospital clus-
ering of patients to obtain efficient standard error estimates.
s with regression modeling, we calculated each patient’s
robability of death with and without CR use at each time
oint and then estimated mortality reduction as the differ-
nce between these 2 rates and averaged for the entire
ohort.
ole of residual confounding in the relationships be-
ween CR and mortality. To quantify residual confound-
ng from unobserved characteristics, we contrasted esti-
ated CR effects obtained from the IV analysis with those
rom regression modeling; we then used the result to adjust
ndings from matching.
ensitivity analysis. As a sensitivity analysis, we repeated
he propensity-based matched analysis including only the
airs with AMI and/or CABG, the most straightforward
ndications for Medicare reimbursement of CR.
esults
f the 601,099 Medicare beneficiaries who met the study’s
ligibility criteria, 12.2% (n  73,049) received 1 or more
R outpatient sessions, and CR users received a mean of 24SD 12.4) (Table 1). The CR users were more likely to be
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Cardiac Rehabilitation and Survival June 30, 2009:25–33ale, white, younger, and not on Medicaid (a health program
or individuals and families with low incomes and resources),
nd to have been admitted for an AMI, CABG, or PCI
rocedure than nonusers. They also had fewer comorbid
onditions and were less likely to have had prior admissions for
MI or CHD, coexisting CHF, peripheral vascular or cere-
rovascular diseases, musculoskeletal conditions, chronic pul-
onary disease, or diabetes.
Although CR users and nonusers differed considerably
aseline Characteristics of Overall Cohort and Matched Pairs
Table 1 Baseline Characteristics of Overall Cohort and Matche
Entire Cohort
Characteristic CR Users Nonusers
Standardized
Difference*
Sample size 73,049 528,050 NA
Propensity score (mean) NA NA NA
Standard deviation NA NA NA
Sociodemographic characteristics of patients
Male 64.0% 50.0% 28.6%
White 96.5% 90.0% 26.3%
Age group (yrs)
65–74 65.7% 47.3% 37.8%
75–84 32.3% 40.0% 16.1%
85 2.0% 12.7% 41.9%
Medicaid at discharge 3.3% 14.1% 38.9%
Index hospitalization (not exhaustive groups)
AMI as principal diagnosis at discharge 36.7% 31.5% 11.0%
CABG as coronary procedure 37.5% 11.6% 63.1%
PCI as coronary procedure 20.3% 17.9% 6.2%
Comorbid conditions
Cardiovascular disease
Prior acute myocardial infarction 2.7% 3.6% 5.0%
Prior any other coronary diagnosis 13.9% 24.4% 26.7%
Hypertensive heart disease 54.0% 54.8% 1.5%
Cardiac arrest 5.6% 5.5% 0.3%
CHF 19.4% 31.2% 27%
Peripheral vascular disease 15.0% 18.5% 9.5%
Cerebrovascular disease 7.1% 10.2% 11.0%
Musculoskeletal condition 15.9% 20.7% 12.5%
Chronic pulmonary disease 15.0% 21.7% 17.4%
Diabetes without complications 22.8% 26.5% 8.5%
Diabetes with complications 2.7% 5.1% 12.0%
Census division of index hospital
New England 5.7% 5.1% 2.7%
Mid Atlantic 12.0% 15.9% 11.4%
South Atlantic 15.4% 21.9% 16.9%
East North Central 25.2% 18.4% 16.6%
East South Central 5.2% 8.7% 13.9%
West North Central 17.2% 6.9% 31.9%
West South Central 7.8% 11.3% 11.7%
Mountain 4.2% 3.9% 1.8%
Pacific 7.4% 8.0% 2.0%
Index hospitalization
Length of stay 4 days 54.5% 40.4% 28.6%
Any-cause hospitalization in prior year 22.8% 36.3% 30.0%
Facility characteristics of index hospitalization
Availability of cardiac catheterization
Yes 69.0% 62.3% 14.1%
Unknown 16.7% 18.2% 3.9%
Medical school affiliation
Yes 46.9% 41.3% 11.3%
Unknown 3.8% 3.9% 0.5%
Standardized difference is the mean difference between groups as a percentage of their pooled
AMI  acute myocardial infarction; CABG  coronary artery bypass graft; CHF  congestive hen clinical and location-of-care measures, matched co- Torts were well balanced on all observable characteristics.
uccessful matches were obtained for 70,040 CR users
ith a like number of nonusers and for 17,298 high-dose
R users (25 or more sessions) with an equal number of
ow-CR users.
In the matched-pair analysis, CR users were less likely
o have died at each time point. For example, cumulative
ortality rates were 2.2% in CR users versus 5.3% in
onusers at 1 year and 16.3% versus 24.6% at 5 years.
irs
Matched Pairs (CR Use) Matched Pairs (CR Dose)
Users Nonusers
Standardized
Difference*
Low-CR
Users
High-CR
Users
Standardized
Difference*
40 70,040 NA 17,298 17,298 NA
0.257 0.251 0.0% 0.532 0.532 0.0%
.170) (0.162) NA (0.115) (0.115)
63.6% 63.6% 0.0% 67.2% 67.2% 0.0%
96.5% 96.5% 0.0% 99.2% 99.2% 0.0%
65.2% 65.2% 0.0% 70.0% 70.0% 0.0%
32.7% 32.7% 0.0% 29.5% 29.5% 0.0%
2.1% 2.1% 0.0% 0.5% 0.5% 0.0%
3.4% 3.4% 0.0% 0.7% 0.7% 0.0%
37.1% 37.1% 0.0% 33.8% 33.8% 0.0%
35.4% 35.4% 0.0% 38.4% 38.4% 0.0%
21.0% 21.0% 0.0% 18.9% 18.9% 0.0%
2.7% 2.7% 0.3% 2.7% 2.8% 0.7%
14.1% 14.4% 0.7% 14.0% 14.0% 0.1%
54.1% 53.0% 2.3% 53.3% 53.6% 0.6%
5.5% 5.6% 0.4% 5.2% 5.3% 0.4%
19.8% 19.8% 0.0% 18.9% 18.8% 0.3%
15.1% 15.4% 0.8% 14.8% 14.7% 0.5%
7.1% 7.4% 0.9% 6.9% 7.1% 0.9%
15.9% 15.4% 1.3% 15.6% 15.3% 0.7%
15.2% 15.6% 1.1% 15.5% 15.2% 0.6%
23.0% 23.1% 0.4% 23.0% 23.1% 0.2%
2.8% 2.8% 0.2% 2.6% 2.7% 0.5%
5.9% 5.9% 0.0% 5.7% 5.8% 0.3%
12.5% 12.5% 0.0% 12.9% 12.9% 0.0%
16.0% 16.0% 0.0% 16.6% 17.0% 1.0%
25.6% 25.6% 0.0% 23.8% 23.1% 1.5%
5.4% 5.4% 0.0% 5.5% 5.8% 1.4%
14.5% 14.5% 0.0% 16.5% 16.0% 1.5%
8.1% 8.1% 0.0% 8.0% 8.3% 1.2%
4.2% 4.2% 0.0% 4.4% 4.2% 1.1%
7.7% 7.7% 0.0% 6.6% 6.9% 1.3%
53.3% 53.2% 0.2% 53.7% 53.9% 0.5%
23.1% 23.4% 0.7% 22.7% 22.6% 0.4%
68.4% 69.0% 1.2% 83.5% 83.3% 0.6%
17.0% 16.8% 0.3% 16.6% 16.7% 0.5%
46.3% 45.0% 2.7% 49.0% 48.2% 1.5%
3.8% 3.9% 0.4% 3.9% 3.7% 0.7%
re; CR  cardiac rehabilitation; NA  not applicable; PCI  percutaneous coronary intervention.d Pa
CR
70,0
(0hese mortality reductions represented relative reduc-
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tatistically significant (p  0.001) (Fig. 1A). In addition,
igh-dose CR users were less likely to die than low-dose
R users (1.1% vs. 2.6% at 1 year and 14.0% vs. 17.2% at
years; p  0.001 in each case) (Fig. 1B). These
ortality reductions from more sessions represented
elative reductions of 58% at 1 year and 19% at 5 years.
All sex, age, and racial groups had lower mortality rates
mong CR users than among matched nonusers (Table 2).
ortality reductions increased progressively with older age
Figure 1 Estimates of Cumulative Mortality Rates for Propensi
All curves begin 1 month after discharge. Differences in cumulative mortality rates
were significant (p  0.0001). Differences in cumulative mortality rates between l
rates between CR users and nonusers were 3.1% in year 1, 2.0% in year 2, 1.8%
mortality rates between high- and low-CR users were 1.4% in year 1, 0.7% in year
All-Cause 5-Year Cumulative Mortality Rates forPairs of CR Use s and Nonusers by Demographi
Table 2 All-Cause 5-Year Cumulative MortalPairs of CR Users and Nonusers by
Participant Groups Number of Matched Pairs
All matched pairs 70,040
By sex and age group
Men 44,550
Age 65–74 yrs 30,003
Age 75–84 yrs 13,790
Age 85 yrs 757
Women 25,490
Age 65–74 yrs 15,678
Age 75–84 yrs 9,135
Age 85 yrs 677
By race
Whites 67,569
Nonwhites 2,471*Estimated mortality rate differences between nonusers and cardiac rehabilind were greater in women than men in each age group.
verall, the cumulative 5-year mortality reduction was
reater in women than men (10.4% vs. 7.1%). Nonwhites
enefited more than whites (9.9% vs. 8.3%, respectively). In
ddition, multivariate analysis in matched pairs found a
reater benefit from CR in older age groups (p  0.001 for
5 to 84 years and p  0.013 for 85 years and older)
ompared with age 65 to 74 years and in women compared
ith men (p  0.001), but no statistically significant
ifference for race (p  0.442).
sed Matched Groups of CR Use
en cardiac rehabilitation (CR) users and nonusers at each time point shown
d high-CR users were all significant (p  0.001). Differences in annual mortality
r 3, 1.5% in year 4, and 1.6% in year 5 (all at p  0.001). Differences in annual
% in year 3, 0.5% in year 4, and 0.3% in year 5 (all significant at p  0.011).
chedracteristics
ates for Matched
ographic Characteristics
Cumulative Mortality Rates
CR Users Nonusers Difference*
16.3% 24.6% 8.3%
18.1% 25.2% 7.1%
14.2% 19.9% 5.7%
24.9% 34.7% 9.8%
47.3% 61.8% 14.5%
14.2% 24.5% 10.4%
11.5% 19.7% 8.2%
17.2% 30.7% 13.4%
34.4% 53.9% 19.5%
16.6% 24.9% 8.3%
18.1% 28.1% 9.9%ty-Ba
betwe
ow- an
in yea
2, 0.8Matc Cha
ity R
Demtation (CR) users were all significantly different than 0 at p  0.001.
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Cardiac Rehabilitation and Survival June 30, 2009:25–33CR use was associated with lower mortality in all clinical
ubgroups. Reductions in 5-year cumulative mortality were
reater in patients with AMIs than in those without AMIs
12.0% vs. 6.1%, respectively, p  0.001) and in patients
ith coexisting CHF than in those without CHF (15.7% vs.
.5%, respectively, p  0.001) (Table 3). When the cohort
f matched pairs was stratified by both AMI diagnosis and
HF, the largest difference in 5-year cumulative mortality
ates was in patients with AMIs who also had CHF (32.5%
n CR users vs. 52.0% in nonusers).
Figure 2 displays the observed and estimated mortality
ates for the full cohort of beneficiaries. In CR nonusers,
bserved mortality rates (Fig. 2A) were slightly higher than
ates adjusted by either regression modeling (Fig. 2B) or IVs
Fig. 2C). In CR users, however, estimated mortality rates
rom regression modeling and IVs were noticeably higher
han observed rates. These comparisons indicate some
election effects and confounding with CR users being
ealthier overall than nonusers on both observed and
nobserved characteristics.
Table 4 summarizes the observed and estimated 1- and
-year mortality rates in CR users and nonusers. Several
oints deserve emphasis. First, mortality rates for both CR
sers and nonusers were dramatically lower in the matched-
airs analysis than in analyses that included the entire
ohort. This is because matched pairs represent a relatively
ealthier subgroup of the cohort. Second, mortality reduc-
ions associated with CR use were lower from each of the
All-Cause 5-Year Cumulative Mortality Rates forMatched Pairs of CR Users and Nonusers by Cli
Table 3 All-Cause 5-Year Cumulative MortalMatched Pairs of CR Users and Non
Participant Groups Number of Matche
All matched pairs 70,040
By presence of AMI diagnosis
AMI 25,966
Without coexistence of CHF 19,044
With coexistence of CHF 6,922
Non-AMI 44,074
Without coexistence of CHF 37,136
With coexistence of CHF 6,938
By type of treatment
CABG 24,809
Without coexistence of CHF 20,185
With coexistence of CHF 4,624
PCI 14,679
Without coexistence of CHF 12,459
With coexistence of CHF 2,220
No coronary procedure 30,552
Without coexistence of CHF 23,536
With coexistence of CHF 7,016
By coexistence of CHF
No 56,180
Yes 13,860
*Estimated mortality rate differences between nonusers and CR user
Abbreviations as in Table 1.nalytic techniques than were observed reductions (e.g., oange of 21.2% to 33.7% at 5 years compared with 58.9%).
ence, adjustment for observed explanatory factors is im-
ortant to reduce confounding. Third, the IV model, which
djusts for both observed and unobserved variables, pro-
ided the lowest mortality reduction associated with CR.
ven then, 1-year mortality was 43.4% and 5-year mortality
as 21.2% relatively lower in CR users than nonusers (both
 0.001). In addition, although the relative reduction in
ortality decreases between 1 and 5 years of follow-up, the
bsolute reduction increases over this period. Similarly, the
nnual mortality reductions are highly significant even in
ear 5 in both matched pairs and IV analyses (Figs. 1 and 2).
Finally, under the propensity-based matched analysis
imited to the 46,889 matched pairs with AMI and/or
ABG, CR users were associated with an 8.9-percentage
oint lower 5-year mortality rate compared with their
onuser counterparts.
iscussion
his study of older Americans with CHD provides strong
vidence of a beneficial relationship between the use of CR and
mproved patient survival. The finding that 5-year mortality in
R users was 21% lower than in comparable beneficiaries who
id not use CR is very similar to the 20% and 23% reductions
eported in the 2 most recent meta-analyses of randomized
rials (14). Moreover, the findings extend to a much broader
pectrum of individuals than did the randomized clinical trials:
Groups
ates for
s by Clinical Groups
rs
Cumulative Mortality Rates
CR Users Nonusers Difference*
16.3% 24.6% 8.3%
18.9% 30.9% 12.0%
13.9% 23.2% 9.3%
32.5% 52.0% 19.5%
14.9% 21.0% 6.1%
12.1% 17.2% 5.0%
29.4% 41.3% 11.9%
13.7% 19.0% 5.3%
11.1% 15.3% 4.2%
25.1% 35.3% 10.2%
14.7% 20.8% 6.1%
12.1% 16.9% 4.8%
29.4% 43.1% 13.7%
20.0% 31.8% 11.8%
15.2% 24.6% 9.4%
36.4% 56.2% 19.8%
12.7% 19.2% 6.5%
30.9% 46.6% 15.7%
all significantly different than 0 at p  0.001.nical
ity R
user
d Pailder patients with CHD, individuals with diverse socioeco-
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linical severity of cardiac disease and comorbidities.
The study was based on an analysis of administrative data
nd used a variety of analytic approaches to control for
otential confounding and increase the validity of findings.
hese techniques include the use of matching, regression
odeling, and IVs to control for potential confounding.
he validity of findings is further supported by a clear
ose-response effect among CR users. Because the 8.9-
ercentage point improvement among AMI and CABG
atients observed in the sensitivity analysis was close to the
.3-percentage point difference observed in the entire cohort,
ur results are robust to alternative cohort specifications.
Figure 2 Crude and Adjusted Cumulative Mortality Rates for CR
and Nonuse in the Entire Study Cohort of Medicare Be
All curves begin 1 month after discharge. Observed and adjusted differences in cumul
point shown were significant (p  0.0001). Adjusted cumulative mortality rates for CR
bit (p  0.001 for 12 months, p  0.01 for 24 and 48 months, and p  0.05 for 36
non-CR use from instrumental variables were 6.0% in year 1, 2.4% in year 2, 2.9% in
ne- and 5-Year Benefit of CR Use by Analytic Technique
Table 4 One- and 5-Year Benefit of CR Use by Analytic Techniq
Mortality Rates*
Observation
(N  601,099)
Propensity-Bas
(70,040
1 yr
CR use 2.2% 2.2
Nonuse 11.6% 5.3
Absolute difference† 9.4% 3.1
Relative reduction‡ 81.0% 58.5
5 yrs
CR use 16.4% 16.3
Nonuse 39.9% 24.6
Absolute difference† 23.5% 8.3
Relative reduction‡ 58.9% 33.7Absolute differences between cardiac rehabilitation (CR) users and nonusers were all significantly differen
n mortality rates are for CR use compared with nonuse.Favorable associations between CR use and survival were
ound in all race, sex, and age groups and in all clinical
ubgroups including patients with coexisting CHF. The dif-
erences in mortality rates in the matched-pair analysis imply
hat one 5-year death would be averted for every 12 patients
ho receive CR (20). Furthermore, the significant reduction in
ear 5 under both matched-pairs and IV analyses suggest that
he benefits associated with CR persist for at least 5 years. The
ndings strongly suggest the need to increase the use of CR in
broad range of patients who are recovering from AMIs or
oronary artery revascularization procedures.
tudy strengths and limitations. Important strengths of
he study are the large size and diverse sociodemographic and
iaries (N  601,099)
ortality rates between cardiac rehabilitation (CR) users and nonusers at each time
om instrumental variables were lower at each time point than rates from single pro-
0 months). Adjusted differences in annual mortality rates between CR use and
1.5% in year 4, and 1.5% in year 5 (all at p  0.001).
tching
)
Regression Modeling
(N  601,099)
Instrumental Variables
(N  601,099)
4.8% 6.0%
10.9% 10.6%
6.1% 4.6%
56.0% 43.4%
28.1% 29.8%
38.0% 37.8%
9.9% 8.0%
26.1% 21.2%Use
nefic
ative m
use fr
and 6
year 3,ue
ed Ma
Pairs
%
%
%
%
%
%
%
%t than 0 at p 0.001. †Absolute difference is in percentage point difference. ‡Relative reductions
c
5
p
r
r
t
e
l
o
m
v
a
b
a
M
s
m
p
o
e
c
s
c
t
a
a
s
s
m
c
p
i
r
H
u
1
p
w
c
p
a
c
H
o
T
1
p
m
a
e
t
u
t
p
s
I
u
s
a
i

a
T
u
l
i
H
c
t
(
r
i
p
e
p
r
b
w
F
m
e
s
C
O
p
b
t
t
n
O
p
a
i
p
(
v
A
T
l
R
T
G
a
e
J
32 Suaya et al. JACC Vol. 54, No. 1, 2009
Cardiac Rehabilitation and Survival June 30, 2009:25–33linical characteristics of the population examined and the
-year follow-up period available that provided nearly 3 million
erson-years of data. The study population included a broad
ange of older Americans with coronary disease who were
eceiving “real world” medical treatment. This contrasts with
he randomized controlled trials of CR, which generally
nrolled selected, less severely ill, and younger individuals. The
arge size and diverse characteristics of the cohort and breadth
f medical and sociodemographic variables permitted close
atching of CR users with CR nonusers and increased the
alidity of our results. Additionally, the inclusion of IVs in the
nalysis helped to control for potential confounding of results
y unobserved differences in disease severity, risk factors,
dherence, or lifestyle variables that were not available in the
edicare database. Comparisons among the 3 techniques
how the value of multiple analytic approaches. The fact that
ortality reductions were one-third lower using IVs than with
ropensity-based matching suggests that extensive matching
n observed variables did not completely eliminate selection
ffects.
Limitations of the study derive from its reliance on Medi-
are claims data as the major data source and the fact that the
tudy period was from 1997 through 2002. These data were
ompiled by Medicare as a special, one-time study. Although
he claims data allowed for adjustment for principal diagnoses
nd the presence of comorbidities, they did not permit explicit
djustment for important measures of heart disease severity
uch as left ventricular ejection fraction, cardiac risk factors
uch as smoking or obesity, important laboratory test results, or
edication regimens. Moreover, the matched-pair analysis
ould not control for the level of patient motivation as a
otential confounder. The benefits of CR would be overstated
f motivation to modify lifestyles and to adhere to medication
egimens were stronger in CR users than among nonusers.
owever, the use of the IV approach should control for such
nobserved characteristics.
Finally, changes in treatment protocols for CHD since the
997 to 2002 period may have influenced the use of CR and
atient survival. Eligibility for Medicare reimbursement of CR
as expanded in 2006 to include patients who received
oronary angioplasty or cardiac transplantation and valve re-
lacement, in addition to the previous indications of stable
ngina, AMI, and CABG surgery (8). Hence, more patients
overed by Medicare may be receiving CR today than in 1997.
owever, CR use remained low in 2005 (21), and the number
f CR facilities changed little between 1997 and 2004 (22).
reatment for CHD, however, has become more intense since
997 with the increased use of early coronary angioplasty in
atients with AMIs, the advent of drug-eluting stents, and
ore aggressive use of cardiac medications such as statins,
ntiplatelet agents, beta-blockers, and angiotensin-converting
nzyme inhibitors. There is no a priori reason, however, to
hink that these treatments would differentially benefit CR
sers more than nonusers. Despite its limitations, this study is
he largest analysis to date of CR in the elderly, a growing oopulation segment in the U.S. and worldwide and a growing
hare of CR users (23).
mplications of findings. This study verified the low overall
se of CR in patients with coronary artery disease (12.2%)
hown in prior studies in the U.S. (14% after AMI and 31%
fter CABG [24] and 35% after AMI in 21 states [21]), 29%
n the United Kingdom (25), 23% in France after AMI (26),
8% in Japan after AMI (27), and 41% in Ontario, Canada,
fter CABG (28). Low use of CR is a global phenomenon.
he confluence of low use of CR and higher survival in CR
sers highlights important clinical, policy, and research chal-
enges. Low CR use occurs despite the endorsement of CR by
mportant professional organizations including the American
eart Association, American College of Cardiology, Ameri-
an Association of Cardiovascular and Pulmonary Rehabilita-
ion (5–7); the Canadian Association of Cardiac Rehabilitation
29); and the European Society of Cardiology (30). Possible
easons for low use of CR include physicians’ skepticism over
ts benefits, variations in access to CR programs in different
arts of the country and in different countries, preference for
xercise or rehabilitation at home over in an institution, and
hysicians’ primary emphasis on cardiac medications and
evascularization procedures. Patient-related factors may also
e operative, including their reluctance to commit to 8 to 12
eeks of CR sessions and logistic or financial impediments.
inally, compared with other interventions, current reimburse-
ent levels for CR may be too low to cover costs (31,32) or
ncourage active marketing of programs by hospitals or free-
tanding facilities.
onclusions
ur study provides strong support for the concept that CR
articipation decreases mortality in older cardiac patients as has
een demonstrated in younger patients in randomized con-
rolled trials. This evidence suggests the importance of initia-
ives to further evaluate its clinical benefits and cost effective-
ess and to consider options for stimulating expanded use.
ptions might include: 1) examining the resource costs of
roviding CR services so that reimbursement rates can be
djusted and appropriate incentives for use created (33,34); 2)
mplementing quality-of-care performance measures for hos-
itals and physicians to encourage referrals to and use of CR
35,36); and 3) considering including CR use as a criterion in
alue-based purchasing initiatives (37).
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